Background
Phase III, open-label RCT. 413 patients with rituximab-refractory indolent NHL (no response or relapse within 6 months of last rituximab dose); 335 had FL. Tested obinutuzumab + bendamustine followed by obinutuzumab maintenance versus bendamustine alone. GADOLIN was pivotal in establishing G-benda for rituximab-refractory FL.
Interventions and follow up
Arm A: Obinutuzumab 1000mg IV (days 1, 8, 15 cycle 1; day 1 cycles 2–6) + bendamustine 90mg/m² IV days 1–2, q28d × 6 cycles; then obinutuzumab 1000mg IV q2mo maintenance × 2 years
Arm B: Bendamustine 120mg/m² IV days 1–2, q28d × 6 cycles (no maintenance)
Primary endpoint: Progression-free survival (investigator-assessed)
Median follow-up: 31.8 months (OS update)
Arm B: Bendamustine 120mg/m² IV days 1–2, q28d × 6 cycles (no maintenance)
Primary endpoint: Progression-free survival (investigator-assessed)
Median follow-up: 31.8 months (OS update)
Results
Median PFS (FL subgroup): Not reached vs 13.8 months, HR 0.48, 95% CI 0.34–0.68, P<.001
Median OS (FL subgroup): Not reached vs 53.9 months, HR 0.67, 95% CI 0.47–0.96, P=.026
ORR: 78.7% vs 74.2%
MRD negativity (end of induction): 86% vs 55%, P=.0002
Median OS (FL subgroup): Not reached vs 53.9 months, HR 0.67, 95% CI 0.47–0.96, P=.026
ORR: 78.7% vs 74.2%
MRD negativity (end of induction): 86% vs 55%, P=.0002
Adverse events
Hematologic/infectious (G-benda vs benda): Grade 3–5 AEs 72.5% vs 65.5%; grade ≥3 neutropenia 35.7% vs 23.6%; grade ≥3 infections 19.3% vs 15.1%.
Infusion-related: Grade ≥3 infusion-related reactions 9.3% vs 1.0%.
Infusion-related: Grade ≥3 infusion-related reactions 9.3% vs 1.0%.
Conclusions
Obinutuzumab + bendamustine followed by obinutuzumab maintenance significantly improved PFS and OS versus bendamustine alone in rituximab-refractory indolent NHL (predominantly FL), establishing G-benda as a standard salvage option in this population.
Key Limitations
The comparator arm (bendamustine monotherapy without maintenance) may be suboptimal — practice often uses BR even in rituximab-refractory disease. The OS benefit, while notable, derived from a crossover-adjusted analysis. Two years of obinutuzumab maintenance adds cost and infusion burden. Subsequent options in this rituximab-refractory, bendamustine-exposed population are limited.
Clinical Context
The FDA approved obinutuzumab + bendamustine followed by obinutuzumab maintenance for rituximab-refractory FL in 2016, with EMA approval following. It remains an ESMO-recognized option for rituximab-refractory FL. With the emergence of bispecific antibodies (mosunetuzumab, epcoritamab) and CAR-T in later lines, the R/R FL landscape has expanded substantially beyond G-benda.